世界のテノホビルアラフェナミド・その併用薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)

GlobalInfoResearchが発行した調査報告書(GIR21JY00001)
◆英語タイトル:Global Tenofovir Alafenamide and Its Combination Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
◆商品コード:GIR21JY00001
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2021年7月
◆ページ数:109
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥469,800見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥704,700見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥939,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

GlobalInfoResearch社の本調査レポートでは、テノホビルアラフェナミド・その併用薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。テノホビルアラフェナミド・その併用薬の種類別市場規模(テノホビルアラフェナミド、エルビテグラビル/コビシスタット/エムトリシタビン/テノホビルアラフェナミド、エムトリシタビン/リルピビリン/テノホビルアラフェナミド、エムトリシタビン/レノホビルアラフェナミド、ビクテグラビル/エントリシタビン/テノホビルアラフェナミド)、用途別市場規模(病院、クリニック、ドラッグセンター、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):Affine Formulations Limited、Beacon Pharmaceuticals、Biocon Limited、Cipla、Flamingo Pharmaceuticals Limited、Gilead Sciences、IPCA Laboratories、Johnson and Johnson、Julphar Bangladesh、Medisist Pharma、Mylan Pharmaceuticals、Natco Pharma、Sun Pharmaceutical Industries、CHIA TAI TIANQING (CTTQ) Pharmaceutical
・メーカー別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:テノホビルアラフェナミド、エルビテグラビル/コビシスタット/エムトリシタビン/テノホビルアラフェナミド、エムトリシタビン/リルピビリン/テノホビルアラフェナミド、エムトリシタビン/レノホビルアラフェナミド、ビクテグラビル/エントリシタビン/テノホビルアラフェナミド
・用途別分析2016年-2026年:病院、クリニック、ドラッグセンター、その他
・テノホビルアラフェナミド・その併用薬の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・テノホビルアラフェナミド・その併用薬のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・テノホビルアラフェナミド・その併用薬のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・テノホビルアラフェナミド・その併用薬の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・テノホビルアラフェナミド・その併用薬の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
【レポートの概要】

The Tenofovir Alafenamide and Its Combination Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Tenofovir Alafenamide and Its Combination Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Tenofovir Alafenamide and Its Combination Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Tenofovir Alafenamide and Its Combination Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Tenofovir Alafenamide
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
Emtricitabine/Rilpivirine/Tenofovir Alafenamide
Emtricitabine/Renofovir Alafenamide
Bictegravir/Emtricitabine/Tenofovir Alafenamide

Market segment by Application, can be divided into
Hospital
Clinic
Drug Center
Other

Market segment by players, this report covers
Affine Formulations Limited
Beacon Pharmaceuticals
Biocon Limited
Cipla
Flamingo Pharmaceuticals Limited
Gilead Sciences
IPCA Laboratories
Johnson and Johnson
Julphar Bangladesh
Medisist Pharma
Mylan Pharmaceuticals
Natco Pharma
Sun Pharmaceutical Industries
CHIA TAI TIANQING (CTTQ) Pharmaceutical

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

【レポートの目次】

1 Market Overview
1.1 Product Overview and Scope of Tenofovir Alafenamide and Its Combination Drugs
1.2 Classification of Tenofovir Alafenamide and Its Combination Drugs by Type
1.2.1 Overview: Global Tenofovir Alafenamide and Its Combination Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Type in 2020
1.2.3 Tenofovir Alafenamide
1.2.4 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
1.2.5 Emtricitabine/Rilpivirine/Tenofovir Alafenamide
1.2.6 Emtricitabine/Renofovir Alafenamide
1.2.7 Bictegravir/Emtricitabine/Tenofovir Alafenamide
1.3 Global Tenofovir Alafenamide and Its Combination Drugs Market by Application
1.3.1 Overview: Global Tenofovir Alafenamide and Its Combination Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global Tenofovir Alafenamide and Its Combination Drugs Market Size & Forecast
1.5 Global Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast by Region
1.5.1 Global Tenofovir Alafenamide and Its Combination Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Tenofovir Alafenamide and Its Combination Drugs Market Size by Region, (2016-2021)
1.5.3 North America Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Tenofovir Alafenamide and Its Combination Drugs Market Drivers
1.6.2 Tenofovir Alafenamide and Its Combination Drugs Market Restraints
1.6.3 Tenofovir Alafenamide and Its Combination Drugs Trends Analysis
2 Company Profiles
2.1 Affine Formulations Limited
2.1.1 Affine Formulations Limited Details
2.1.2 Affine Formulations Limited Major Business
2.1.3 Affine Formulations Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.1.4 Affine Formulations Limited Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Affine Formulations Limited Recent Developments and Future Plans
2.2 Beacon Pharmaceuticals
2.2.1 Beacon Pharmaceuticals Details
2.2.2 Beacon Pharmaceuticals Major Business
2.2.3 Beacon Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.2.4 Beacon Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Beacon Pharmaceuticals Recent Developments and Future Plans
2.3 Biocon Limited
2.3.1 Biocon Limited Details
2.3.2 Biocon Limited Major Business
2.3.3 Biocon Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.3.4 Biocon Limited Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Biocon Limited Recent Developments and Future Plans
2.4 Cipla
2.4.1 Cipla Details
2.4.2 Cipla Major Business
2.4.3 Cipla Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.4.4 Cipla Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Cipla Recent Developments and Future Plans
2.5 Flamingo Pharmaceuticals Limited
2.5.1 Flamingo Pharmaceuticals Limited Details
2.5.2 Flamingo Pharmaceuticals Limited Major Business
2.5.3 Flamingo Pharmaceuticals Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.5.4 Flamingo Pharmaceuticals Limited Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Flamingo Pharmaceuticals Limited Recent Developments and Future Plans
2.6 Gilead Sciences
2.6.1 Gilead Sciences Details
2.6.2 Gilead Sciences Major Business
2.6.3 Gilead Sciences Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.6.4 Gilead Sciences Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Gilead Sciences Recent Developments and Future Plans
2.7 IPCA Laboratories
2.7.1 IPCA Laboratories Details
2.7.2 IPCA Laboratories Major Business
2.7.3 IPCA Laboratories Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.7.4 IPCA Laboratories Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 IPCA Laboratories Recent Developments and Future Plans
2.8 Johnson and Johnson
2.8.1 Johnson and Johnson Details
2.8.2 Johnson and Johnson Major Business
2.8.3 Johnson and Johnson Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.8.4 Johnson and Johnson Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Johnson and Johnson Recent Developments and Future Plans
2.9 Julphar Bangladesh
2.9.1 Julphar Bangladesh Details
2.9.2 Julphar Bangladesh Major Business
2.9.3 Julphar Bangladesh Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.9.4 Julphar Bangladesh Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Julphar Bangladesh Recent Developments and Future Plans
2.10 Medisist Pharma
2.10.1 Medisist Pharma Details
2.10.2 Medisist Pharma Major Business
2.10.3 Medisist Pharma Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.10.4 Medisist Pharma Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Medisist Pharma Recent Developments and Future Plans
2.11 Mylan Pharmaceuticals
2.11.1 Mylan Pharmaceuticals Details
2.11.2 Mylan Pharmaceuticals Major Business
2.11.3 Mylan Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.11.4 Mylan Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Mylan Pharmaceuticals Recent Developments and Future Plans
2.12 Natco Pharma
2.12.1 Natco Pharma Details
2.12.2 Natco Pharma Major Business
2.12.3 Natco Pharma Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.12.4 Natco Pharma Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Natco Pharma Recent Developments and Future Plans
2.13 Sun Pharmaceutical Industries
2.13.1 Sun Pharmaceutical Industries Details
2.13.2 Sun Pharmaceutical Industries Major Business
2.13.3 Sun Pharmaceutical Industries Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.13.4 Sun Pharmaceutical Industries Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
2.14 CHIA TAI TIANQING (CTTQ) Pharmaceutical
2.14.1 CHIA TAI TIANQING (CTTQ) Pharmaceutical Details
2.14.2 CHIA TAI TIANQING (CTTQ) Pharmaceutical Major Business
2.14.3 CHIA TAI TIANQING (CTTQ) Pharmaceutical Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.14.4 CHIA TAI TIANQING (CTTQ) Pharmaceutical Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 CHIA TAI TIANQING (CTTQ) Pharmaceutical Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Tenofovir Alafenamide and Its Combination Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Tenofovir Alafenamide and Its Combination Drugs Players Market Share
3.2.2 Top 10 Tenofovir Alafenamide and Its Combination Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Tenofovir Alafenamide and Its Combination Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Tenofovir Alafenamide and Its Combination Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Tenofovir Alafenamide and Its Combination Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Application (2016-2021)
5.2 Tenofovir Alafenamide and Its Combination Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
6.2 North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
6.3 North America Tenofovir Alafenamide and Its Combination Drugs Market Size by Country
6.3.1 North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2026)
6.3.2 United States Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
7.2 Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
7.3 Europe Tenofovir Alafenamide and Its Combination Drugs Market Size by Country
7.3.1 Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2026)
7.3.2 Germany Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7.3.3 France Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Market Size by Region
8.3.1 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Region (2016-2026)
8.3.2 China Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.5 India Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
9.2 South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
9.3 South America Tenofovir Alafenamide and Its Combination Drugs Market Size by Country
9.3.1 South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Market Size by Country
10.3.1 Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

...

【掲載企業】

Affine Formulations Limited、Beacon Pharmaceuticals、Biocon Limited、Cipla、Flamingo Pharmaceuticals Limited、Gilead Sciences、IPCA Laboratories、Johnson and Johnson、Julphar Bangladesh、Medisist Pharma、Mylan Pharmaceuticals、Natco Pharma、Sun Pharmaceutical Industries、CHIA TAI TIANQING (CTTQ) Pharmaceutical

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のテノホビルアラフェナミド・その併用薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)(Global Tenofovir Alafenamide and Its Combination Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。